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Abstract
The association between promoter methylation status and survival was investigated in a large
cohort of women with breast cancer, participants in the Long Island Breast Cancer Study Project.
Archived tumor tissues (n=839) were collected from women diagnosed with a first primary
invasive or in situ breast cancer in 1996-1997. Vital status was followed through the end of 2005
with a mean follow up time of 8 years. Promoter methylation of 8 breast cancer-related genes was
assessed by MethyLight. The frequencies of methylation for HIN1, RASSF1A, DAPK1, GSTP1,
CyclinD2, TWIST, CDH1 and RARβ were 62.9%, 85.2%, 14.1%, 27.8%, 19.6%, 15.3%, 5.8%
and 27.6%, respectively. Since survival rates of in situ and invasive breast cancers are
substantially different, survival analyses were conducted within 670 invasive cases with complete
data on all genes. Age-adjusted Cox-proportional hazards models revealed that GSTP1, TWIST
and RARβ methylation was significantly associated with higher breast cancer-specific mortality.
Methylation of GSTP1 and RARβ were significantly associated with higher all-cause mortality.
To investigate the relationship between the number of methylated genes and breast cancer-specific
mortality, we included previously published MethyLight data on p16 and APC methylation status.
Breast cancer-specific mortality increased in a dose-dependent manner with increasing number of
methylated genes (Ptrend = 0.002), although confidence intervals were wide. Our results suggest
that promoter methylation, particularly for a panel of genes, has the potential to be used as a
biomarker for predicting prognosis in breast cancer.
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Breast cancer is the most common cancer and second cause of cancer-death among females
in most Western countries [1]. Although early detection and novel treatments have improved
outcomes and survival rates for women with breast cancer, disease progression is still poorly
understood. Recently, gene expression status [1] is being used to predict cancer outcomes,
but its prognostic relevance is still undergoing evaluation. Therefore, research efforts
continue to focus on identifying more sensitive and specific biomarkers that can reliably
predict clinical outcomes and enhance treatment options.
Epigenetic alterations are one of the most common molecular alterations in human neoplasia
[2]. In particular, aberrant promoter methylation occurs in numerous genes in cancer
development and progression [3]. Among these genes, APC [4], p16 [5], RASSF1A [6],
DAPK1 [7], CDH1 [8], RARβ [9], GSTP1 [10], CyclinD2 [11], HIN1 [12] and TWIST [13]
are frequently methylated in breast cancer. Different studies have confirmed the hypothesis
that aberrant methylation at specific genes contributes to the malignant phenotype and
survival rates of breast cancer. Nimmrich et al. [14] reported that hypermethylation of
PITX2 was negatively associated with PITX2 gene expression in cell lines and positively
associated with breast cancer disease progression in lymph node negative and steroid
hormone receptor positive breast cancer patients. Several studies by Kioulafe et al. [15-17]
showed that promoter hypermethylation in RASSF1A, Kallikrein 10 (KLK10) and cystatin
M (CST6) in tumor tissue are independent prognostic marker in early stage breast cancer
patients. More recently methylation of 773 genes was examined in breast tumors and 8
methylation classes were identified; associations between methylation class with age, tumor
size, alcohol intake and total dietary folate were observed [18].
We previously reported positive associations between survival and promoter methylation
status of BRCA1 using methylation-specific PCR [19] and APC and p16 using MethyLight
[20] in a large cohort of women with a first primary breast cancer who were participants in
the Long Island Breast Cancer Study Project. In the present study, we expanded tumor DNA
methylation analysis to an additional eight tumor suppressor genes (HIN1, RASSF1A,
DAPK1, GSTP1, CyclinD2, TWIST, CDH1 and RARβ) to investigate the association of
aberrant methylation with clinicopathologic characteristics and all-cause and breast cancer-
specific mortality in women with breast cancer.
MATERIALS AND METHODS
This project draws upon resources of the Long Island Breast Cancer Study Project
(LIBCSP), a population-based study of English-speaking residents of Nassau and Suffolk
counties of Long Island. Details of the study participants and study design for the parent
case-control and follow-up studies have been described previously [21-23]. The study
protocol was approved by the Institutional Review Boards of the collaborating institutions.
Study population
Briefly, eligible participants were adult women who were newly diagnosed with a first
primary in situ or invasive breast cancer between August 1, 1996, and July 31, 1997, and
were residents of Nassau and Suffolk counties on Long Island NY. A total of 1,508 women
with breast cancer participated in the baseline interview. At diagnosis, the participants
ranged in age from 20 to 98 years; 94% self-reported their race as white, 4% as black, and
2% as other, which reflects the underlying population of these two counties [21-23]. As part
of the follow-up study, the case participants, or their next of kin, were re-interviewed
approximately five years after diagnosis.
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Information used in this study was obtained as part of the: (1) baseline in-home interview;
(2) follow-up telephone interview; (3) medical record abstraction (complete course of
treatment and tumor characteristics for the primary breast cancer), which occurred at
baseline and again at follow-up; (4) the National Death Index (NDI); and (5) retrieved
archived tumor tissue, as described previously [21-24].
Subject interviews. Structured questionnaires were interviewer-administered to assess
demographic characteristics and breast cancer-related factors.
Medical records. First course of treatment for the primary breast cancer, and characteristics
of estrogen and progesterone receptor (ER and PR) status were abstracted from medical
records. Among cases included in the present project, 337 (59.8%) were ER+/PR+; 91
(16.1%) were ER+/PR-; 21 (3.7%) were ER-/PR+; and 115 (20.4%) were ER-/PR-.
Vital status at the follow-up. The NDI was used to ascertain all-cause and breast cancer-
specific mortality among case participants, as previously described [23]. Participants
diagnosed with breast cancer in 1996–1997 were followed until December 31, 2005, for a
mean of 8.0 yrs (range, 0.3-9.4). Among the entire cohort of 1508 women, 308 (20.4%)
deaths occurred, of which 164 (53.2%) were due to breast cancer. In the present study, a
total of 179 all-cause deaths and 99 (55.3%) breast cancer-specific deaths were observed
among the participant subset with available tumor DNA (n=859).
Tumor block retrieval, microdissection and DNA extraction. REMARK criteria for reporting
tumor studies are used throughout this report [25].
Archived pathology blocks for the first primary breast cancer from 962 (63.8%) women
were successfully retrieved from the 33 hospitals in the Long Island study area [24]. After
review by the study pathologist (HH), 859 tumor tissue blocks (89.3%) were appropriate for
laboratory analyses. There were no differences in demographic and clinicopathological
features between cases with and without tumor blocks available for methylation analysis in
our study, except for age, post-menopausal status, and percent invasive tumors. At
diagnosis, compared to cases without tumor samples, cases with available tumor samples
were: older (mean age, 59.6 yrs vs 57.9 yrs; P=0.005); were more frequently post-
menopausal (70.7% vs 64.6%; P=0.01); and a greater percent had invasive tumors (87.8% vs
80.1%; P<0.001).
Tumor tissues were isolated from 2 × 10 micron thick slides of paraffin sections by
microdissection; at least 90% of the cells were tumor cells. Tumor DNA was isolated by
adding 30 μl of proteinase K-digestion buffer (50mM Tris, pH 8.1, 1 mM EDTA, 0.5%
Tween 20, 10 μg/ml proteinase K) and incubating overnight at 37°C. Proteinase K was
inactivated by heating at 95°C for 10 min and centrifugation.
Laboratory analysis of gene promoter methylation
MethyLight methods for p16 and APC were reported previously [20]. Among 859 cases
with tumor DNA, 20 subjects were excluded because of insufficient DNA. Thus, a total of
839 tumor DNAs were available for this project, however, only 765 (95 in situ and 670
invasive breast cancer cases) had complete data on all 10 genes. Tumor DNAs first
underwent bisulfite modification to convert unmethylated cytosine residues to uracil using
the CpGnome DNA Modification Kit (Chemicon International, Purchase, NY) following the
protocol from the manufacturer. Sodium bisulfite treated DNA was analyzed by the
MethyLight technique as described previously [26]. The primers and probes for the selected
genes and β-actin (ACTB) were previously described [12;26-28]. Specificity of the reactions
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for methylated DNA was confirmed separately using CpGenome™ Universal methylated
DNA (Chemicon, MA, USA) and unmethylated human sperm DNA. TaqMan PCR reactions
with primers specific for the bisulfite-converted methylated sequence for a particular locus
and with the ACTB reference primers were performed separately. The values obtained in
these two TaqMan analyses were used as a measure of the degree of methylation at that
locus. Ct value for ACTB ranged from 25.7 to 39.5 with a median of 29.9. Relative
quantification was determined based on the threshold cycles of the gene of interest and of
the internal reference gene. The percentage of methylation at a specific locus was calculated
by the 2-ΔΔCT method, where ΔΔCT = (CT,Target-CT,Reference)sample - (CT,Target-
CT,Reference)fully methylated DNA [29] and multiplying by 100. Percentage methylation for
selected genes was dichotomized to methylated or unmethylated using a cut-off of 4%, as
used in a number of prior publications (e.g.,[30]). All samples were assayed in duplicate and
the MethyLight assay was further validated by using mixtures of fully methylated and
unmethylated DNA to give 0, 1, 5, 10, 25, 50 or 100% methylation. Intra- and interassay
coefficients of variation (CVs) were 0.5 and 1.9, respectively.
To validate the 2-ΔΔCT method, the amplification efficiencies of the test genes and reference
gene, ACTB, were examined using serial dilutions of DNA with a 100-fold range and gene-
specific primers of each gene and ACTB. The ΔCT (CT,Target gene - CT,Reference) was
calculated for each DNA dilution and a plot of the log DNA dilution vs ΔCT was made. All
amplification efficiencies were similar (data not shown).
Statistical analysis
DNA methylation status was dichotomized using 4% as a cut-off point (≥4% as methylated
vs. <4% as unmethylated) based on previous validated data [31;32]. While in agreement
with a prior study [33], promoter methylation was evident in <10% of the tumor samples for
CDH1; thus, this gene was omitted from the analyses focused on the relationship between
risk factors and patient characteristics (Table 1), due to small cell sizes and unstable results.
For the remaining markers, the Chi-square test was used to examine the association between
each gene promoter marker and selected patient factors, which were considered as
categorical variables including age at diagnosis (<50 years, >50 years), race (white, other),
menopausal status (pre-, post-), body mass index (BMI = weight in kilograms (kg) divided
by height in meters squared (m2) (<25, >25)), family history of breast cancer (no, yes in
mother or sister), history of benign breast disease (yes, no), cancer type (in situ, invasive)
and ER/PR status (both positive, either positive, both negative).
Since survival rates of in situ and invasive breast cancers are substantially different, survival
analyses were only conducted within 670 invasive cases. Cox proportional hazard regression
[34] was used to estimate the hazard ratios (HR) and 95% confidence intervals (95% CI) for
the association between gene promoter methylation status and breast cancer-specific or all-
cause mortality. We first considered each gene separately in relation to mortality, adjusting
only for age at diagnosis. Then we used a backward elimination strategy to test for potential
confounding by the following covariates (race, BMI, family history of breast cancer, and
history of benign breast disease) on the associations between methylation markers and breast
cancer-specific or all-cause mortality. None of these covariates changed the effect estimate
for any of the methylation markers by 10% or more [35], and thus were not included in the
final models. We did not consider as potential confounders, clinical characteristics
(including tumor size, nodal involvement or first course of treatment), because under our
hypothesis, these factors can be considered to be on the causal pathway between the tumor
marker and the study outcome (mortality). As epidemiologic methodologists have long
argued, inclusion of such mediators in our models would result in biased estimates of effect
[36]. Thus, our underlying hypothesis is that these tumor markers of methylation are not
influenced by clinical characteristics such as tumor size and nodal involvement, but instead
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occur prior to disease progression. All statistical analyses were completed using Statistical
Analysis System 9.0 (SAS Institute, Cary, NC).
RESULTS
We examined promoter methylation status for a panel of 8 genes in a population-based
cohort of 839 women with breast cancer. Among the 839 cases with tumor tissue DNA, we
obtained methylation data on all 8 genes for 765 tumors; failures were due to insufficient
amount or poor quality DNA. Promoter hypermethylation of HIN1, RASSF1A, DAPK1,
GSTP1, CyclinD2, TWIST, CDH1 and RARβ was observed in 62.9%, 85.2%, 14.1%,
27.8%, 19.6%, 15.3%, 5.8% and 27.6% of the samples, respectively.
For those 7 genes for which the prevalence of methylation was greater than 10%, the
relationships with selected clinical/pathological parameters are summarized in Table 1.
Methylation in DAPK1 and CyclinD2 was more frequent in women with breast cancer over
50 years of age at diagnosis (P=0.007 and P=0.02, respectively), and CyclinD2 and TWIST
methylation was more frequent among women who were postmenopausal at the time of
diagnosis (both, P=0.02). In situ case tumors had more frequent methylation of HIN1 than
invasive cancers (P=0.02). Hormone receptor status of the case tumor was also positively
associated with a high frequency of HIN1 and RASSF1A methylation (P=0.02 and P=0.009,
respectively). Specifically, patients with ER+ or PR+ tumors had more frequent methylation
of HIN1 and RASSF1A than those with ER- or PR- tumors.
Among the 308 (20.4%) participants who died within the follow-up period, tumor DNA
methylation data were available for 161 women with invasive breast cancer. As shown in
Table 2, methylation status of GSTP1, TWIST and RARβ in the case tumor was associated
with higher breast cancer-specific mortality, after adjustment for age at diagnosis. Compared
to cases with an unmethylated promoter in tumor tissue, those with a methylated promoter
had a 71%, 67% and 78% increased risk of dying from breast cancer at the end of follow up
for GSTP1 (HR: 1.71; 95% CI: 1.10-2.65), TWIST (HR: 1.67; 95% CI: 1.01-2.79) and
RARβ (HR: 1.78; 95% CI: 1.15-2.76), respectively. Similar but somewhat weaker
associations between methylation status in these genes and all-cause mortality were also
observed; the associations with GSTP1 and RARβ were significant (HR: 1.49; 95% CI:
1.08-2.07 and HR: 1.45; 95% CI: 1.05-2.02, respectively).
We also considered joint gene effects, combining cases into 4 groups according to the
number of genes methylated. For this analysis we also included MethyLight data on p16 and
APC methylation status from our prior studies [20]. As shown in Table 3, a dose-response
association emerged; as the number of methylated genes increased, the magnitude of the
associations with all-cause and breast cancer-specific mortality increased (Ptrend=0.02,
Ptrend=0.002, respectively). With 6-10 genes methylated, the breast cancer-specific mortality
HR was 2.45 (95%CI: 1.16-5.17). Similar but weaker associations were observed for all-
cause mortality (HR: 1.49; 95%CI: 0.87-2.57). Figure 1 presents Kaplan-Meier breast
cancer-specific survival curves, which illustrates the decreasing survival associated with
increasing number of genes methylated.
DISCUSSION
Patient age, axillary lymph node status, tumor size, histologic grade, hormone receptor
status and HER2 status have been used historically to determine prognosis in women with
breast cancer [37]. More recently, gene expression data have been used with two
commercial laboratory tests available to assist in treatment decisions [1]. However these
assays have limitations suggesting that other approaches maybe of use. We began
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conducting studies to understand the relationship between gene-specific methylation and
prognosis using data on the population-based cohort of women diagnosed with a first
primary breast cancer in the LIBCSP. We previously reported positive associations between
promoter methylation status of BRCA1, APC and p16 and poor disease outcome among
women with breast cancer [19;20]. In the present study, we evaluated methylation in 8
additional genes in the same cohort of breast cancer cases. Our univariate results showed
that promoter hypermethylation of three tumor suppressor genes, GSTP1, TWIST1 and
RARβ was associated with breast cancer-specific mortality, while hypermethylation in
GSTP1 and RARβ showed significant associations with all-cause mortality. We also found
significant inverse associations between decreasing breast cancer survival and increasing
number of genes methylated.
Few prior studies have investigated tumor methylation status and prognosis. While we
observed an association with TWIST1 methylation and prognosis, a prior smaller study
(N=151) [38] did not find an association with sentinel lymph node tumor status, a marker of
metastasis. In contrast, our positive results for methylation in GSTP1 and poorer prognosis
had been reported previously in a study of 100 breast cancer cases [39]. Another study
reported that RASSF1A methylation was associated with poorer prognosis [16]; and
although we also found a positive association with RASSF1A methylation and breast cancer
mortality (HR: 1.77; 95%CI: 0.86-3.67), the effect estimate was not significant possibly due
to the high frequency of positive tumors. In a study of 99 tumors from carriers of BRCA1 or
2 mutations, methylation of six genes; ERα, TWIST, Cyclin D2, CDH1, APC and RASSF1
was elevated for at least one of the histopathological variables tested (ER, HER2, lymph
node status, tumor stage and recurrent or metastatic disease) [40]. One previous study [41]
that examined 7 genes, along with our own prior study with 3 genes [20], observed that a
panel of hypermethylated genes has higher predictive power than single genes in
determining breast cancer survival. In the current study, data on 10 genes were analyzed,
and a trend was observed in which increasing number of methylated genes was associated
with poorer survival. With 6-10 genes methylated, the HR was 2.45 (1.16-5.17). These
findings suggest that hypermethylation-mediated silencing of multiple tumor-suppressor
genes influences prognosis of breast cancer.
We found few correlations of tumor methylation status with clinical/pathological factors.
While older women had more frequent DAPK1 and CyclinD2 methylation then younger
women, there were fewer women <50 years of age at diagnosis in our study cohort.
Similarly, associations were found for CyclinD2 and TWIST1 methylation and menopausal
status and for methylation in HIN1 and RASSF1A and ER/PR status, but cell sizes were
limited. Although the higher frequency of methylation for RASSF1A among women with
ER/PR positive tumors has been observed previously [38], most of these associations await
confirmation by others. Thus, these results should be interpreted with caution.
Since we expanded our study with additional breast cancer-related tumor suppressor genes
on the same study population and used the same tumor tissue blocks as our previous study
[20], the limitations in the present study are as previously described. First, since the blocks
were collected from multiple hospitals with non-standardized protocols, some
clinicopathologic parameters which are known as independent breast cancer prognostic
factors were not completed on the medical records for all cases. This limited our more
detailed investigation of the predictive effect of gene methylation status and prognosis.
However, among women with this information available, we explored the association
between methylation status and these clinical covariates, according to cancer type, and
found no substantial differences. Second, the frequency of hypermethylation of CDH1 and
the number of deaths in some of the subgroups are relatively small. Thus, some subgroup
analyses are based on small number of patients, which are reflected in the wide confidence
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intervals. These results should be interpreted carefully. Third, the overwhelming proportion
of our study participants are white women with breast cancer (which reflects the underlying
racial distribution of the geographic area of the LIBCSP), and thus our results are not
generalizable to other race/ethnicities. Another limitation of our study is the possibility of
misclassification on the cause of death. Uncertainty regarding cause of death on death
certificates is an ongoing issue in most studies of cause-specific mortality, including our
own. In the current study, we used the National Death Index, which has been validated and
is considered the gold standard source of mortality data for epidemiologic studies [42].
Advantages of our study approach include a large population-based cohort of women
diagnosed with a first primary breast cancer, with both biospecimens and a comprehensive
assessment of factors suspected of influencing prognosis. This approach allows for greater
generalizability and higher sensitivity, since multiple factors were taken into consideration
in examining the associations with survival. Moreover, there are few epidemiologic studies
that have reported on the prognostic value of multiple gene promoter methylation status in
breast cancer. In summary, we examined promoter methylation status of 8 additional breast
cancer-related genes and explored their relationship with clinical/pathological factors as well
as survival among a cohort of women diagnosed with breast cancer. Our results suggest that
promoter methylation, particularly for a panel of multiple genes, could offer additional value
to predict prognosis of breast cancer.
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Kaplan–Meier breast cancer survival curves for number of methylated genes in tumor tissue
among a population-based cohort of women diagnosed with a first primary invasive breast
cancer in 1996–1997 and followed for 8 years, Long Island Breast Cancer Study Project.
Black carrying 0–1, red 2–3, blue 4–5 or yellow 6–10 methylated genes
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